CLINICAL_TRIALS
trial_result
· 2014-04-02
Clinical Trial Update: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome [Phase 3]
Summary
An extension study of CORLUX (mifepristone) for endogenous Cushing's syndrome completed, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Corcept Therapeutics | Conditions: Cushing's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2014-04-02